natgillin/translations-raw huggingface dataset:
The other side effects that have been experienced by some patients taking Pioglitazone Krka are: common (may affect up to 1 in 10 people)
Pri nekaterih bolnikih, ki so jemali zdravilo Pioglitazone Krka, so se pojavili drugi neželeni učinki: pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
The other side effects that have been experienced by some patients taking pioglitazone: Common (may affect up to 1 in 10 people)
Drugi neželeni učinki, ki so se pojavili nekaterim bolnikom med uporabo pioglitazona, so: Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
The other side effects that have been experienced by some patients when pioglitazone is taken with other antidiabetic medicines are:
Pri nekaterih bolnikih, ki so jemali zdravilo Sepioglin skupaj z drugimi antidiabetičnimi zdravili, so se pojavili naslednji drugi neželeni učinki:
The other side of the tablet is debossed with the number “7314”.
Druga stran tablete ima vtisnjeno številko »7314«.
The other study (456 patients) compared Bydureon with insulin glargine as add-on treatment to metformin with or without a sulphonylurea.
V drugi študiji (pri 456 bolnikih) so zdravilo Bydureon kot dodatno zdravilo pri zdravljenju z metforminom s sulfonilsečnino ali brez nje primerjali z insulinom glarginom.
The other study compared Januvia with metformin, used on their own, in 1,058 patients; three additional studies compared Januvia with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
V drugi študiji so zdravilo Januvia primerjali z metforminom pri 1 058 bolnikih, ki so obe zdravili jemali samostojno; v treh dodatnih študijah so zdravilo Januvia primerjali s placebom, obe zdravili so dodajali drugim zdravilom proti sladkorni bolezni; glimepiridu (drugi vrsti sulfonilsečnine), z metforminom ali brez njega, pri 441 bolnikih ali kombinaciji metformina in rosiglitazona (agonista PPAR–gama) pri 278 bolnikih ali ustaljenemu odmerku insulina, z metforminom ali brez njega, pri 641 bolnikih.
The other study compared Ristaben with metformin, used on their own, in 1,058 patients; three additional studies compared Ristaben with placebo when they were added to other diabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
V drugi študiji so pri 1 058 bolnikih primerjali zdravilo Ristaben z metforminom, oba uporabljena kot samostojni zdravili; v treh dodatnih študijah so zdravilo Ristaben primerjali s placebom, kadar sta bila dodana drugim zdravilom proti sladkorni bolezni: glimepiridu (drugi vrsti sulfonilsečnine) z metforminom ali brez njega pri 441 bolnikih, kombinaciji metformina in rosiglitazona (agonista PPAR-gama) pri 278 bolnikih ali ustaljenemu odmerku inzulina z metforminom ali brez njega pri 641 bolnikih.
The other study compared Tesavel with metformin, used on their own, in 1,058 patients; three additional studies compared Tesavel with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
V drugi študiji so zdravilo Tesavel primerjali z metforminom pri 1 058 bolnikih, ki so obe zdravili jemali samostojno; v treh dodatnih študijah so zdravilo Tesavel primerjali s placebom, obe zdravili so dodajali drugim zdravilom proti sladkorni bolezni; glimepiridu (drugi vrsti sulfonilsečnine), z metforminom ali brez njega, pri 441 bolnikih ali kombinaciji metformina in rosiglitazona (agonista PPAR–gama) pri 278 bolnikih ali ustaljenemu odmerku insulina, z metforminom ali brez njega, pri 641 bolnikih.
The other study compared Xelevia with metformin, used on their own, in 1,058 patients; three additional studies compared Xelevia with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
V drugi študiji so zdravilo Xelevia primerjali z metforminom pri 1 058 bolnikih, ki so obe zdravili jemali samostojno; v treh dodatnih študijah so zdravilo Xelevia primerjali s placebom, obe zdravili so dodajali drugim zdravilom proti sladkorni bolezni; glimepiridu (drugi vrsti sulfonilsečnine), z metforminom ali brez njega, pri 441 bolnikih ali kombinaciji metformina in rosiglitazona (agonista PPAR–gama) pri 278 bolnikih ali ustaljenemu odmerku insulina, z metforminom ali brez njega, pri 641 bolnikih.
The other study, which compared RoActemra injected under the skin with RoActemra given by infusion, showed that RoActemra injected under the skin was no less effective in achieving a response after 6 months.
Druga študija, v kateri so primerjali injiciranje zdravila RoActemra pod kožo z dajanjem zdravila z infuzijo, je pokazala, da ni bilo zdravilo, injicirano v podkožje, nič manj učinkovito pri doseganju odziva v šestih mesecih.
The other subject used 24.6 IU/kg once weekly for 8.5 months.
Drugi bolnik je uporabljal odmerek 24,6 i.e./kg enkrat na teden 8,5 mesecev.
The other tablet ingredients are: copovidone, sorbitan laurate, anhydrous calcium hydrogen phosphate, colloidal anhydrous silica, sodium stearyl fumarate.
Pomožne snovi v tableti so: kopovidon, sorbitan lavrat, brezvodni kalcijev hidrogenfosfat, koloidni brezvodni silicijev dioksid, natrijev stearilfumarat.
The other two active substances, abacavir and lamivudine, are nucleoside reverse- transcriptase inhibitors (NRTIs).
Drugi dve zdravilni učinkovini, abakavir in lamivudin, sta nukleozidna zaviralca reverzne transkriptaze (nucleoside reverse-transcriptase inhibitors – NRTI).
The other two studies (516 patients) examined the effects of Xyrem on excessive daytime sleepiness and other symptoms of narcolepsy, either taken alone or as an add-on to the patient’s existing dose of modafinil (a stimulant medicine used to treat narcolepsy).
V drugih dveh študijah (pri 516 bolnikih) so proučevali učinke zdravila Xyrem na prekomerno dnevno zaspanost in na druge simptome narkolepsije, pri čemer se je zdravilo jemalo samostojno ali kot dodatek k bolnikovemu obstoječemu odmerku modafinila (stimulansa, ki se uporablja za zdravljenje narkolepsije).
The other two studies compared Dukoral (containing recombinant cholera toxin) with placebo in over 22,000 people in Peru.
V drugih dveh študijah so cepivo Dukoral (ki je vsebovalo rekombinantni toksin kolere) primerjali s placebom pri več kot
The other two studies compared ritonavir-boosted Prezista with other protease inhibitors chosen on the basis of the patient’s previous treatments and predicted response, in a total of 628 patients who had taken many anti-HIV medicines in the past.
V preostalih dveh študijah so zdravilo Prezista, spodbujeno z ritonavirjem, primerjali z drugimi zaviralci proteaze, ki so bili izbrani na podlagi predhodnih zdravljenj bolnika in predvidenega odziva, pri skupno 628 bolnikih, ki so v preteklosti jemali različna zdravila za zdravljenje okužb z virusom HIV.
The other two studies compared Telzir with lopinavir (another protease inhibitor), both of which were boosted with ritonavir.
V drugih dveh študijah so zdravilo Telzir primerjali z lopinavirjem (drugim zaviralcem proteaze), obe zdravili pa sta bili ojačani z ritonavirjem.
The other two studies in rheumatoid arthritis showed that Kineret was more effective than placebo when used as an add-on to methotrexate.
Drugi dve študiji revmatoidnega artritisa sta pokazali, da je bilo zdravilo Kineret učinkovitejše od placeba, če se je uporabljalo kot dodatek metotreksatu.
The other two studies involved a total of 1,159 patients with later stage disease, where Azilect was added to the patients’ existing treatment including levodopa.
V drugi dve študiji je bilo vključenih skupno 1 159 bolnikov z boleznijo v kasnejši fazi, pri katerih je bilo zdravilo Azilect dodano k bolnikovemu obstoječemu zdravljenju, ki je vključevalo levodopo.
The other two studies lasted longer: one compared Sycrest with olanzapine over nine weeks in patients who had come from the short-term studies; and the other was a 12-week ‘add on’ study, in which 326 patients who were already being treated with another medicine (lithium or valproic acid) were also given either Sycrest or placebo.
Preostali dve študiji sta trajali dlje: v eni so zdravilo Sycrest devet tednov primerjali z olanzapinom pri bolnikih, ki so zaključili kratkotrajni študiji; druga študija pa je bila 12-tedenska študija dodajanja zdravila, v kateri so 326 bolnikom, ki so že jemali drugo zdravilo (litij ali valprojsko kislino), poleg tega dajali še bodisi zdravilo Sycrest ali placebo.
The other two studies showed that the 150-mg monthly tablets and the injections were more effective than the 2.5-mg once-daily tablets at increasing bone density in the spine and the hip.
Drugi dve študiji sta pokazali, da so 150- miligramske mesečne tablete in injekcije pri povečevanju kostne gostote v hrbtenici in kolkih učinkovitejše od 2,5-miligramskih tablet, ki se jemljejo enkrat na dan.
The otheringredients are lactose monohydrate, low-substituted hydroxypropyl cellulose, tartaric acid, sodium laurylsulfate and magnesium stearate in the tablet core as well as lecithin (soybeans), poly(vinyl alcohol), talc, titanium dioxide (E 171) and xanthan gum in the film-coating.
Pomožne snovi so: laktoza monohidrat, hidroksipropil celuloza (nizko substituirana), vinska kislina, natrijev lavrilsulfat in magnezijev stearat v jedru tablete ter lecitin (sojina zrna), polivinil alkohol, smukec, titanov dioksid (E 171) in ksantan gumi v filmski oblogi.
The outcome of DRESS is favorable in most cases upon discontinuation of PROTELOS and after initiation of corticosteroid therapy when necessary.
V večini primerov je izid sindroma DRESS ugoden po prekinitvi jemanja zdravila PROTELOS in uvedbi zdravljenja s kortikosteroidi, če je le-to potrebno.
The outcome was reported as recovered in eight cases, improved in two cases, unchanged at time of reporting in five and unknown in 10 cases.
V rezultatih je bilo poročano, da je v osmih primerih prišlo do ozdravitve, v dveh do izboljšanja, v petih je bilo stanje v času poročanja nespremenjeno, v 10 pa je bilo stanje neznano.
The outer and inner needle caps should be removed.
Odstranite zunanji in notranji pokrovček igle.
The outer and inner needle caps should be removed.
Odstraniti je treba zunanji in notranji pokrovček igle.
The outer and intermediate package should be checked to verify the product and patient-specific- label located on the top of the box and on the intermediate bag.
Zunanjo in vmesno ovojnino je treba pregledati in se prepričati, da je na vrhu škatle in na vmesni vreči nalepka, specifična za bolnika.
The outer cap should be kept to remove the used needle.
Shrani naj zunanji pokrovček, da bo z njim odstranil uporabljeno iglo.
The outer cap should be kept to remove the used needle.
Shranite zunanji pokrovček, da boste z njim odstranili uporabljeno iglo.
The outer layer is beige and labelled with the following:
Zunanja plast je rjavkasto bele barve z eno od naslednjih oznak:
The outer shipping box should be opened to verify the product and patient-specific labels located on the top of the insulated container.
Zunanjo transportno škatlo je treba odpreti, da se preveri zdravilo in nalepke, specifične za bolnika, ki se nahajajo na vrhu izoliranega vsebnika.
The outer shipping box should be opened to verify the product and patient-specific labels located on the top of the insulated container.
Zunanjo transportno škatlo je treba odpreti, da se preveri zdravilo in nalepke, specifične za bolnika, ki so na vrhu izoliranega vsebnika.
The outer surface of the backing layer is imprinted with ‘capsaicin 8%’.
Na zunanji plasti je vtisnjena oznaka „capsaicin 8 %“.
The outer surface of the backing layer is imprinted with ‘capsaicin 8%’.
Na zunanji plasti je vtisnjena oznaka „capsaicin 8%“.
The outside is tan-coloured and is imprinted with Leganto 1 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 1 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 3 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 3 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 4 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 4 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 6 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 6 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 8 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Leganto 8 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 1 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 1 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 3 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 3 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 4 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 4 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 6 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 6 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 8 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 8 mg/24 h.
The outside of the backing layer is beige and labelled with “Exelon”,
Zunanji del krovne plasti je rjavkasto bele (beige) barve z oznakami “Exelon”,
The outside of the backing layer is beige and labelled with “Prometax”,
Zunanji del krovne plasti je rjavkasto bele (beige) barve z oznakami “Prometax”,
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 1 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 1 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 2 mg/24 h, 4 mg/24 h, 6 mg/24 h ali
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 2 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 2 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 3 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 3 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 4 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 4 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 6 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 6 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 8 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Leganto 8 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 1 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 1 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h ali
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 2 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 3 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 3 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 4 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 4 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 6 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 6 mg/24 h’.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 8 mg/24 h’.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 8 mg/24 h’.
The outside of the OptiSet can be cleaned by wiping it with a damp cloth.
Zunanjost injekcijskega peresnika OptiSet lahko čisti z vlažno krpo.
The outside of the OptiSet can be cleaned by wiping it with a damp cloth.
Zunanjost injekcijskega peresnika OptiSet lahko čistite z vlažno krpo.
The outside of the OptiSet can be cleaned by wiping it with a damp cloth.
Zunanjost OptiSeta lahko očistite tako, da ga obrišete z vlažno krpico.
The overall adverse reaction profile of Cerdelga is based on pooled results from the primary analysis periods of two pivotal studies and one 4-year, long term study, with a total of 152 patients who received eliglustat for a median duration of 51.9 weeks (range 0.1 to 210.9 weeks) and between the ages of 16 - 69 years.
Celotni profil neželenih učinkov za zdravilo Cerdelga temelji na združenih rezultatih iz obdobij primarne analize v dveh ključnih študijah in eni 4-letni, dolgotrajni študiji pri skupno 152 bolnikih, ki so eliglustat prejemali v mediani trajanja 51,9 tedna (razpon od 0,1 do 210,9 tedna) ter v razponu starosti od 16 do 69 let.
The overall amount of cortisol absorbed into the blood was around 20% lower in patients taking Plenadren compared with patients taking conventional hydrocortisone treatment.
Skupna količina kortizola, absorbiranega v kri, je bila pri bolnikih, ki so jemali zdravilo Plenadren, približno za 20 % nižja v primerjavi z bolniki, ki so prejemali standardno zdravljenje s hidrokortizonom.
the overall antihyperglycaemic activity of rosiglitazone has not been fully elucidated in man and it cannot be ruled out that the metabolite may contribute to the activity.
Prispevek glavnega metabolita (parahidroksisulfata) k celotnemu antihiperglikemičnemu delovanju rosiglitazona pri človeku še niso dodobra pojasnili in ni izključeno, da morda tudi ta metabolit prispeva k delovanju.
The overall clearance of amifampridine is predominantly due to metabolism by N-acetylation and acetylator phenotype has a greater effect on an individual’s metabolism and elimination of amifampridine than does elimination by renal function (See Table 4).
A je v prvi vrsti odgovorna presnova z N-acetilacijo; fenotip acetilatorja pa ima večji učinek na presnovo posameznika in izločanje amifampridina kot izločanje z delovanjem ledvic (glejte preglednico 4).
The overall clinical data reflect exposure of 127 TTR amyloid polyneuropathy patients to 20 mg of tafamidis meglumine administered daily for an average of 538 days (ranging from 15 to 994 days).
Celokupni klinični podatki kažejo izpostavljenosti 127 bolnikov s TTR amiloidno polinevropatijo, ki so povprečno 538 dni (razpon od 15 do 994 dni) prejemali 20 mg tafamidis meglumina na dan.
The overall combined treatment duration in all studies was up to 21 months.
V vseh kliničnih preskušanjih je zdravljenje trajalo do 21 mesecev.
The overall completion rate was significantly higher for patients on oral aripiprazole (43 %) than for oral haloperidol (30 %).
Celotni delež dokončanja je bil pri bolnikih, ki so dobivali peroralni aripiprazol, značilno večji (43 %) kot pri tistih, ki so dobivali peroralni haloperidol (30 %).
The overall decision of the visual PET scan assessment is subject-based and based on a binary outcome as ‘positive’ or ‘negative‘.
Skupna odločitev pri vizualnem vrednotenju PET-posnetkov se nanaša na preiskovanca in temelji na binarnem rezultatu kot "pozitivno" ali "negativno".
The overall duration of treatment is at the specialist physician’s discretion (see section 4.4).
Skupno trajanje zdravljenja je odvisno od presoje specialista (glejte poglavje 4.4).
The overall duration of treatment with EQUIOXX solution for injection or EQUIOXX oral paste will be dependent on the response observed, but should not exceed 14 days
Skupno trajanje zdravljenja z EQUIOXX raztopino za injiciranje ali EQUIOXX peroralno pasto bo odvisno od učinka, vendar naj ne bi preseglo 14 dni.
The overall duration of treatment with EQUIOXX solution for injection or EQUIOXX oral paste will be dependent on the response observed, but should not exceed 14 days.
Skupno trajanje zdravljenja z EQUIOXX raztopino za injiciranje ali EQUIOXX peroralno pasto je odvisno od učinka, vendar naj ne bi preseglo 14 dni.
The overall duration of treatment with i.v. lacosamide is at the physician’s discretion; there is experience from clinical trials with twice daily infusions of lacosamide for up to 5 days
Skupno trajanje zdravljenja z intravenskim lakozamidom je po presoji zdravnika; izkušnje iz kliničnih preskušanj z dvakrat dnevnim infundiranjem lakozamida so za uporabo zdravila do 5 dni.
The overall evidence suggests a possible increased risk of breast cancer in women taking oestrogen- only therapy that is dependent on the duration of therapy.
Zbrani dokazi kažejo na zvečano tveganje za raka dojke pri ženskah, ki uporabljajo samo estrogensko zdravljenje; to tveganje je odvisno od trajanja zdravljenja.
The overall exposure and Cmax of parathyroid hormone were slightly increased (22% and 56%, respectively) in a group of 8 male and 8 female subjects with mild-to-moderate renal impairment (creatinine clearances of 30 to 80 mlmin) compared with a matched group of 16 subjects with normal renal function.
Celokupna izpostavitev obščitničnemu hormonu in Cmax obščitničnega hormona sta bila v skupini 8 moških in 8 žensk z blago do zmerno okvaro ledvic (očistek kreatinina od 30 do 80 ml/min) rahlo zvišana (celokupna izpostavitev za 22% in Cmax za 56%) v primerjavi z ujemajočo se skupino 16 preiskovancev z normalno ledvično funkcijo.
The overall extent of fentanyl exposure in subjects with common cold without prior treatment with nasal vasoconstrictor is comparable to that in healthy subjects.
Skupna stopnja izpostavljenosti fentanilu je pri prehlajenih osebah, ki se ne zdravijo z nosnim vazokonstriktorjem, primerljiva z zdravimi osebami.
The overall frequency of urinary tract infection reported as adverse event was similar in patients treated with empagliflozin 25 mg and placebo (7.6%) and higher in empagliflozin 10 mg (9.3%).
Celokupna pogostnost okužb sečil, o kateri so poročali kot o neželenem učinku, je bila podobna pri bolnikih, zdravljenih z empagliflozinom 25 mg in s placebom (7,6 %), za empagliflozin 10 mg pa je bila višja (9,3 %).
The overall frequency of urinary tract infection reported as adverse event was similar in patients treated with empagliflozin 25 mg and placebo and higher in patients treated with empagliflozin 10 mg (see section 4.8).
Celokupna pogostnost okužb sečil, o kateri so poročali kot o neželenem učinku, je bila podobna pri bolnikih, zdravljenih z empagliflozinom 25 mg in placebom in višja pri bolnikih, zdravljenih z empagliflozinom 10 mg (glejte poglavje 4.8).
The overall frequency of volume depletion (including the predefined terms blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolaemia, orthostatic hypotension, and syncope) was similar in patients treated with empagliflozin (empagliflozin 10 mg: 0.5%, empagliflozin 25 mg: 0.3%) and placebo (0.3%).
Celokupna pogostnost zmanjšanja volumna (vključno s predhodno opredeljenimi pojmi znižanje krvnega tlaka (ambulantno), znižanje sistoličnega krvnega tlaka, dehidracija, hipotenzija, hipovolemija, ortostatska hipotenzija in sinkopa) je bila podobna pri bolnikih, zdravljenih z empagliflozinom (empagliflozin 10 mg: 0,5 %, empagliflozin 25 mg: 0,3 %) in placebom (0,3 %).